Volcano Corporation  

(Public, NASDAQ:VOLC)   Watch this stock  
Find more results for VOLC
19.33
-0.06 (-0.31%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 19.12 - 19.55
52 week 16.37 - 24.62
Open 19.15
Vol / Avg. 610,301.00/580,769.00
Mkt cap 1.00B
P/E     -
Div/yield     -
EPS -0.64
Shares 51.93M
Beta 0.20
Inst. own 117%
May 12, 2014
VOLCANO CORPORATION Annual Shareholder Meeting (Estimated) Add to calendar
May 2, 2014
Q1 2014 VOLCANO CORPORATION Earnings Conference Call - 5:00PM EDT - Add to calendar
May 2, 2014
Q1 2014 VOLCANO CORPORATION Earnings Release - 4:00PM EDT - Add to calendar
Mar 11, 2014
VOLCANO CORPORATION at Barclays Healthcare Conference
Feb 24, 2014
Q4 2013 VOLCANO CORPORATION Earnings Conference Call - Webcast
Feb 24, 2014
Q4 2013 VOLCANO CORPORATION Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -19.84% -8.76%
Operating margin -20.88% -7.60%
EBITD margin - 5.28%
Return on average assets -9.34% -3.98%
Return on average equity -23.05% -9.74%
Employees 1,565 -
CDP Score - -

Address

SUITE 500, 3721 VALLEY CENTRE DRIVE
SAN DIEGO, CA 92130
United States - Map
+1-800-2284728 (Phone)
+1-858-7200325 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Volcano Corporation (Volcano) designs, develops, manufactures and commercializes a range of precision guided therapy tools, including intravascular ultrasound (IVUS), and fractional flow reserve (FFR), products. The Company is facilitating the adoption of functional percutaneous interventional (PCI), in which its FFR technology is used to determine whether or not a stent is necessary, and IVUS is used to guide stent placement and optimization. It markets its products to physicians and technicians who perform PCI procedures in hospitals and to other personnel who make purchasing decisions on behalf of hospitals. Its products consist of multi-modality consoles, which are marketed as stand-alone units or as customized units that can be integrated into a range of hospital-based interventional surgical suites called catheterization laboratories (cath labs).

Officers and directors

Ronald A. Matricaria Chairman of the Board, Lead Independent Director
Age: 70
Bio & Compensation  - Reuters
R. Scott Huennekens President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John T. Dahldorf Chief Financial Officer
Age: 56
Bio & Compensation  - Reuters
Dale C. Flanders Ph.D. President - Axsun Division
Bio & Compensation  - Reuters
Michele Perrino President, Europe, Africa, Middle East, and India Operations
Age: 42
Bio & Compensation  - Reuters
Jorge J. Quinoy President - U.S. & APLAC Commercial Sales
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
David M. Sheehan Chief Operating Officer
Age: 50
Bio & Compensation  - Reuters
Darin M. Lippoldt Executive Vice President, Chief Compliance Officer, General Counsel, Secretary
Age: 47
Bio & Compensation  - Reuters
John Onopchenko Executive Vice President - Strategy, Business Development and Integration
Age: 53
Bio & Compensation  - Reuters
Daniel J. Wolterman Director
Bio & Compensation  - Reuters